MYC and breast cancer: For example, NTZ was identified as an MYC inhibitor in breast cancer cells using an HTS screening system [60]; NTZ could act as a moderate inhibitor of the STAT3 pathway [61]; inhibition of the Wnt signaling activity by NTZ could be independent of APC but involves PAD2 targeting and subsequent increase in the deamination and turnover of β-catenin in colon cancer cells [62].